| 股號 / 名稱 | 現金及約當現金 | 流動資產 | 總資產 |
| TMO 賽默飛世爾科技 | 129,320,855,383.68 | 743,499,455,226.3 | 3,601,318,525,391.88 |
| ABT 美國雅培 | 162,414,775,068.48 | 780,157,335,492.54 | 3,475,338,883,053.3 |
| LH Labcorp Holdings Inc. | 4,512,228,664.72 | 121,394,225,197.64 | 589,717,738,244.83 |
| DGX 奎斯特診斷 | 19,919,993,964.12 | 90,499,141,907.28 | 539,017,216,866.18 |
| A 安捷倫 | 55,941,452,697.96 | 149,336,312,577.66 | 444,444,977,151.54 |
| BIO Bio-Rad Laboratories, Inc. | 16,451,496,612.54 | 96,115,561,930.71 | 326,229,677,508.24 |
| ILMN Illumina Inc | 33,093,919,684.8 | 90,180,931,141.08 | 211,610,159,523.0 |
| QGEN QIAGEN N.V. | 24,454,497,382.47 | 52,715,654,697.76 | 187,400,748,072.66 |
| NTRA Natera, Inc. | 34,732,768,772.88 | 52,789,575,058.75 | 84,564,415,654.42 |
| TEM Tempus AI, Inc. | 19,080,363,036.42 | 41,076,714,071.08 | 75,285,835,207.1 |
| GH Guardant Health, Inc. | 33,522,517,765.79 | 43,424,282,177.64 | 60,851,253,893.97 |
| VCYT Veracyte, Inc. | 9,531,080,690.3 | 18,289,959,314.26 | 47,297,766,371.36 |
| NEO NeoGenomics, Inc. | 4,631,207,670.2 | 12,139,040,666.84 | 43,029,828,111.86 |
| BLLN BillionToOne, Inc. | 17,457,933,623.88 | 20,727,485,604.43 | 23,219,712,325.31 |
| CSTL Castle Biosciences, Inc. | 1,976,597,995.33 | 10,854,169,235.08 | 17,857,256,314.38 |
| 4169 泰宗 | 896,730,000 | 1,561,198,000 | 2,104,265,000 |
| 6598 ABC-KY | 449,173,000 | 934,031,000 | 1,073,322,000 |
載入數據中...
和癌症診斷相關的產業概念股
癌症診斷概念股相關指標排名
癌症診斷每月營收
癌症診斷每股盈餘
癌症診斷每股淨值
癌症診斷損益表
癌症診斷總資產
癌症診斷負債和股東權益
癌症診斷現金流量表
癌症診斷利潤比率
癌症診斷營業費用率拆解
癌症診斷杜邦分析
癌症診斷ROE / ROA
癌症診斷經營週轉能力
癌症診斷營運週轉天數
癌症診斷現金股利發放率
癌症診斷財務結構比率
癌症診斷流速動比率
癌症診斷利息保障倍數
癌症診斷現金流量分析
癌症診斷營業現金流對淨利比
癌症診斷盈餘再投資比率
癌症診斷月營收成長率
癌症診斷營收成長率
癌症診斷毛利成長率
癌症診斷營業利益成長率
癌症診斷稅後淨利成長率
癌症診斷每股盈餘成長率
癌症診斷本益比評價
癌症診斷股價淨值比評價
癌症診斷現金股利殖利率
癌症診斷平均現金股息殖利率
癌症診斷董監持股比例
癌症診斷董監持股質押比例